Type 2 diabetes. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will receive 3 capsules of 1000 milligrams of taurine (product by karen Co. and made in The Iran) for 8 weeks a day. Intervention 2: Control
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients with Type 2 Diabetes Patients who use glucose lowering oral medications are well controlled by their blood glucose levels. Body mass index 35-25 kg /m 2 will be included in the study. age range from 30-60 years
Exclusion criteria
Exclusion criteria: Use of multi-vitamin and mineral supplements over the past 3 months. Taking corticosteroids and non-steroidal anti-inflammatory drugs. Taking insulin Patients with polycystic ovary syndrome Patients with chronic diseases such as cardiovascular, renal and hepatic disorders, and hypothyroidism and hyperthyroidism Having certain physiological conditions such as pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of adiponectin. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of adiponectin via ELISA kit.;Level of irisin. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of irisin via ELISA kit.;Level of fibroblast growth factor-21 (FGF-21). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of fibroblast growth factor-21 (FGF-21) via ELISA kit.;Level of sirtuin-1. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of sirtuin-1 via ELISA kit.;Level of fasting blood sugar (FBS). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of fasting blood sugar (FBS) by enzymatic method.;Level of insulin. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of insulin by enzymatic method.;Level of hemoglobin A1C. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of hemoglobin A1C by enzymatic method.;HOMA-IR scores. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of HOMA-IR score using formula.;Serum level of total cholesterol (TC). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of total cholesterol (TC) level via enzymatic kit.;Serum level of triglyceride. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of triglyceride (TG) level via enzymatic kit.;Serum level of HDL. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of HDL level via enzymatic kit.;Serum level of LDL. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of LDL using friedewald equation.;Serum level of total antioxidant capacity (TAC). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of total antioxidant capacity (TAC) by spectrophotometr | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of the body composition. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Assess body composition using the body composition analyzer.;Physical activity level. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Via IPAQ questionnaire.;Assessment of dietary intake. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: 3-day food record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactVahid Maleki
Tabriz University of Medical Sciences
Outcome results
None listed